Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT06829381
Recruiting Not applicable

Tailored One Anastomosis Gastric Bypass

NCT06829381 · tracked via the Priya Life Science Israel tracker
Sponsor
Tel-Aviv Sourasky Medical Center
Phase
Not applicable
Started
2025-01-29
Last updated
2025-07-24

Condition(s) studied

Metabolic and Bariatric Surgery

Investigational drug(s) / intervention(s)

Tailored BPL lengthControl - BPL 180 cm

Tailored BPL length: Total bowel length measure and BPL will be 40% of total bowel length ensuring at least 250 cm common channel

Control - BPL 180 cm: Total bowel length measure and BPL will be180 cm

Study summary

One Anastomosis Gastric Bypass (OAGB) is the most common metabolic and bariatric surgery (MBS) in Israel, recognized for its effectiveness in achieving sustainable weight loss and mitigating obesity-related diseases. The metabolic outcomes of OAGB are significantly influenced by the length of the biliopancreatic limb (BPL). The objective of this study is to determine whether tailoring the BPL length to the total small bowel length (TSBL) results in more effective weight loss compared to patients undergoing OAGB with a fixed BPL of 180 cm. Efficacy and safety of this approach will also be evaluated, ensuring it does not lead to long-term morbidity or negatively impact patients' quality of life.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18 years) undergoing OAGB Exclusion Criteria: * Patients \<18 years, pregnant women, or those lacking decision-making capacity Prior bariatric surgery Short bowel (\<450 cm)

Primary outcome measure(s)

  • weight loss — 6 months, one year, and 3 years after surgery
    Total weight loss will be calculated as - preoperative weight-last follow-up weight/preoperative weight \* 100

Trial sites (1)

FacilityCityRegionStatus
Tel Aviv Sourasky Medical Center Tel Aviv Israel Recruiting

More Tel-Aviv Sourasky Medical Center trials in Israel

Emotional Release After Trigger Point Needling to Treat Myofascial Pain of the Head and Neck - Prospective Study Enrolling by invitation
Tele-Pulmonary Rehabilitation For COPD Patients Living in Peripheral Areas Recruiting
Changes in Energy Expenditure (EE) in Transsexuals Undergoing Hormonal Therapy Enrolling by invitation
Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD Recruiting
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06829381 on ClinicalTrials.gov ↗ ← All trials in Israel